| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.10498 |
| P698 | PubMed publication ID | 12015762 |
| P50 | author | Mef Nilbert | Q42752494 |
| Pär-Ola Bendahl | Q92965822 | ||
| P2093 | author name string | Ake Borg | |
| Roger Willén | |||
| Anjila Koul | |||
| P2860 | cites work | Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers | Q28145813 |
| PTEN1 is frequently mutated in primary endometrial carcinomas | Q28250937 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase | Q30439814 | ||
| Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity | Q33774967 | ||
| Two pathogenetic types of endometrial carcinoma | Q34713298 | ||
| Alteration of p16 and p15 genes in human uterine tumours | Q36617950 | ||
| beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis | Q36622495 | ||
| Inhibition of H-Ras transformation by the PTEN/MMAC1/TEP1 tumor suppressor gene | Q40896708 | ||
| Alterations of the Rb gene and its association with Ki-ras activation and p53 inactivation in endometrial adenocarcinoma | Q41585955 | ||
| p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis | Q41672720 | ||
| Microsatellite instability in sporadic endometrial carcinoma | Q46250416 | ||
| Somatic Mutations of the PTEN/MMAC1 Gene in Fifteen Japanese Endometrial Cancers: Evidence for Inactivation of Both Alleles | Q48379390 | ||
| Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia | Q49275056 | ||
| Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers | Q52537916 | ||
| Clinical significance of microsatellite instability in endometrial carcinoma | Q53331560 | ||
| Endometrial carcinoma associated with hyperplasia--immunohistochemical study of angiogenesis and p53 expression | Q53427314 | ||
| Mutations of the beta-catenin gene in endometrial carcinomas. | Q54994747 | ||
| The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer | Q57240098 | ||
| CLINICO-PATHOLOGICAL FEATURES AND p53 EXPRESSION IN LEFT-SIDED SPORADIC COLORECTAL CANCERS WITH AND WITHOUT MICROSATELLITE INSTABILITY | Q57337219 | ||
| Mutational Analysis of thePTENGene in Endometrial Carcinoma and Hyperplasia | Q63199224 | ||
| p16INK4andp15INK4BAlterations in Primary Gynecologic Malignancy | Q63641166 | ||
| Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in stage I-II endometrial carcinoma | Q69745069 | ||
| Endometrial carcinoma associated with hyperplasia | Q70888771 | ||
| K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient | Q71763535 | ||
| Low frequency of CDKN2 mutation in endometrial carcinomas | Q71988088 | ||
| Colorectal cancer with and without microsatellite instability involves different genes | Q73031255 | ||
| Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma | Q73117118 | ||
| Alteration of p16 and p15 genes in common epithelial ovarian tumors | Q73302855 | ||
| PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma | Q73374555 | ||
| K-ras mutations in endometrial carcinomas with microsatellite instability | Q73444099 | ||
| Favorable survival associated with microsatellite instability in endometrioid endometrial cancers | Q73588824 | ||
| PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases | Q73622060 | ||
| Identification of TP53 Gene Mutations in Uterine Corpus Cancer with Short Follow-up | Q74087825 | ||
| Concomitant Endometrial Hyperplasia in Patients with Endometrial Carcinoma | Q74506996 | ||
| Microsatellite instability and somatic mutations in endometrial carcinomas | Q77450372 | ||
| K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients' outcome | Q77763896 | ||
| Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability | Q77916764 | ||
| Nuclear localization of beta-catenin in normal and carcinogenic endometrium | Q78015141 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endometrial carcinoma | Q18555222 |
| P304 | page(s) | 2369-2379 | |
| P577 | publication date | 2002-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis | |
| P478 | volume | 94 |
| Q34082455 | Alteration of the k-ras gene expression in atypical and nonatypical hyperplastic endometrium |
| Q37854068 | Aromatase inhibition: a potential target for the management of recurrent or metastatic endometrial cancer by letrozole: more questions than answers? |
| Q35085296 | Capillary electrophoresis and its application in the clinical laboratory |
| Q39668107 | Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study |
| Q36410067 | Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment |
| Q37827340 | Emerging therapeutic targets in endometrial cancer |
| Q33781274 | Genetics of endometrial cancers |
| Q83855411 | Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas |
| Q33750187 | MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases |
| Q37225495 | Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1. |
| Q36772096 | Molecular carcinogenesis of endometrial cancer |
| Q44771919 | Molecular characterization of uterine clear cell carcinoma |
| Q40252326 | Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations |
| Q35640925 | Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification |
| Q35065032 | Molecular pathogenesis and prognostic factors in endometrial carcinoma |
| Q47131591 | Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer |
| Q42796769 | Novel TP53 gene mutation and correlation with p53 immunohistochemistry in a mixed epithelial carcinoma of the endometrium. |
| Q34396070 | Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers |
| Q28181035 | PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms |
| Q37270432 | PTEN: a new guardian of the genome. |
| Q36276560 | Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer |
| Q35911350 | Personalized therapy in endometrial cancer: Challenges and opportunities |
| Q36731185 | Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know |
| Q90778927 | Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study |
| Q39454208 | Targeted Endometrial Cancer Therapy as a Future Prospect |
| Q38053414 | The PI3K/AKT/mTOR Pathway as a Therapeutic Target in Endometrial Cancer |
| Q37631697 | The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer |
| Q47333181 | The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma. |
| Q36151896 | The genomics and genetics of endometrial cancer |
| Q45410745 | Three-dimensional nuclear telomere architecture changes during endometrial carcinoma development |
| Q47686988 | p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas |
Search more.